Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corline Biomedical ABFRA:IZ7 -2.52%43 Gross Margin % is 102.26% as of Mar. 2026, which is 51% below its 10-year median of 208.36. GuruFocus rates FRA:IZ7 with a GF Score™ of 43/100 and a GF Value™ of €0.45. The stock has 3 warning signs investors should review. Among 732 Biotechnology companies, Corline Biomedical AB ranks better than 83.47% on this metric.
Corline Biomedical AB gross margin has been in long-term decline. The average rate of decline per year is -15.3%.
The historical rank and industry rank for Corline Biomedical AB's Gross Margin % or its related term are showing as below:
FRA:IZ7'
s Gross Margin % Range Over the Past 10 Years
Min: 81.37 Med: 208.36 Max: 1747.49
Current: 89.32
During the past 13 years, the highestGross Margin % of Corline Biomedical AB was 1747.49%. The lowest was 81.37%. And the median was 208.36%.
FRA:IZ7's Gross Margin % is ranked better than 83.47% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs FRA:IZ7: 89.32
Corline Biomedical AB had a gross margin of 102.26% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Corline Biomedical AB was -15.30% per year.
Corline Biomedical AB (FRA:IZ7) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Corline Biomedical AB had a gross margin of 102.26% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Corline Biomedical AB Gross Margin % Related Terms
Corline Biomedical AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for Corline Biomedical AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IZ7 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Corline Biomedical AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corline Biomedical AB Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corline Biomedical AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Corline Biomedical AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Corline Biomedical AB (FRA:IZ7) has a Gross Margin % of 102.26% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Corline Biomedical AB and its competitors. This is 51% below median its historical median of 208.36. Over the past decade, Corline Biomedical AB's Gross Margin % has ranged from 81.37 to 1,747.49. According to the industry distribution chart, Corline Biomedical AB ranks #121 out of 732 companies in the Biotechnology industry, placing it in the top 16.5%.
Is Corline Biomedical AB's Gross Margin % too high?
Corline Biomedical AB's current Gross Margin % of 102.26% is 51% below median its 10-year median of 208.36. Over the past 10 years, this metric has ranged from a low of 81.37 to a high of 1,747.49. The Biotechnology industry median Gross Margin % is 60.91. Corline Biomedical AB's value of 102.26% is 67.9% above this industry median. Based on the distribution chart, Corline Biomedical AB ranks #121 out of 732 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corline Biomedical AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Corline Biomedical AB's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Corline Biomedical AB ranks #121 out of 732 companies for Gross Margin %. This places Corline Biomedical AB in the top 17% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Corline Biomedical AB's value of 102.26% is 67.9% above this benchmark. Historically, Corline Biomedical AB's own Gross Margin % has ranged from 81.37 to 1,747.49 over the past decade. While the company's 10-year median is 208.36 vs. the industry median of 60.91, Corline Biomedical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corline Biomedical AB's current Gross Margin % of 102.26% is 67.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Corline Biomedical AB and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corline Biomedical AB's current Gross Margin % is 102.26%, which is 51% below median its own 10-year median of 208.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corline Biomedical AB stock overvalued right now?
Corline Biomedical AB (FRA:IZ7) has a current Gross Margin % of 102.26%. The stock's GF Value™ is €0.45, compared to a current price of €1.55 — trading 243.3% above its estimated fair value. The current Gross Margin % is 102.26%, which is 51% below median its 10-year median of 208.36 and 67.9% above the Biotechnology industry median of 60.91. Corline Biomedical AB's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Corline Biomedical AB (FRA:IZ7), the current Gross Margin % is 102.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corline Biomedical AB (FRA:IZ7) Overvalued in 2026?
Based on GuruFocus' analysis, Corline Biomedical AB stock appears to be overvalued.
The current stock price of €1.55 is trading 243.3% above its estimated GF Value™ of €0.45.
Key valuation signals for FRA:IZ7:
Gross Margin %: 102.26% (51% below median its 10-year median of 208.36)
GF Value™: €0.45 vs. price of €1.55 (243.3% above fair value)
Industry Position: 67.9% above the Biotechnology median (#121 of 732)
No single metric tells the full story. See the FRA:IZ7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
43GF Score
Get the complete analysis for FRA:IZ7
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IZ7 has been successfully added to your 
